2-(1-benzyl-1H-imidazol-5-yl)acetonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(1-benzyl-1H-imidazol-5-yl)acetonitrile
• 英文别名: 2-(3-Benzylimidazol-4-yl)acetonitrile
• 化学式: C₁₂H₁₁N₃
• mdl: MFCD18381911
• 分子量: 197.239
• InChiKey: JMMYTVRVOOMPDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  41.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(1-benzyl-1H-imidazol-5-yl)acetonitrile 在 氢氧化钾 、 sodium hydride 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 (4S)-4-benzyl-3-[2-(3-benzylimidazol-4-yl)acetyl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  A versatile, enantioselective, stereocontrolled synthesis of (1S,2R)-imidazoleglycerol

  摘要：

  An efficient (21% overall yield), enantio- and diastereoselective, 11-step synthesis of (1S,2R)-imidazoleglycerol has been developed. The key steps are the stereoselective hydroxylation of an acyloxazolidinone enolate, the alkylation of a thioester with (MOMOCH(2))(2)CuLi and the stereodivergent reduction of the resulting ketone. The scope of the reaction of the enolate derived from 10 with heteroatom electrophiles has been studied. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0040-4039(96)02138-7
• 作为产物：
  描述：

  1-苄基-5-羟甲基-1H-咪唑 在 氯化亚砜 作用下， 生成 2-(1-benzyl-1H-imidazol-5-yl)acetonitrile
  参考文献：
  名称：

  A versatile, enantioselective, stereocontrolled synthesis of (1S,2R)-imidazoleglycerol

  摘要：

  An efficient (21% overall yield), enantio- and diastereoselective, 11-step synthesis of (1S,2R)-imidazoleglycerol has been developed. The key steps are the stereoselective hydroxylation of an acyloxazolidinone enolate, the alkylation of a thioester with (MOMOCH(2))(2)CuLi and the stereodivergent reduction of the resulting ketone. The scope of the reaction of the enolate derived from 10 with heteroatom electrophiles has been studied. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0040-4039(96)02138-7

文献信息

• Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
  申请人：SAVIRA PHARMACEUTICALS GMBH

  公开号：US20140038990A1

  公开（公告）日：2014-02-06

  The present invention relates to a compound having the general formula (Di), (Dii), or (Diii), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有一般式（Di）、（Dii）或（Diii）的化合物，可选地为药学上可接受的盐、溶剂合物、多型体、共药、共晶、前药、互变异构体、消旋体、对映体或二对映体或其混合物，这些化合物在治疗、改善或预防病毒性疾病方面是有用的。此外，还披露了特定的联合疗法。
• Potential histamine H2-receptor antagonists. 4. Benzylhistamines
  作者：John C. Emmett、Graham J. Durant、C. Robin Ganellin、Anthony M. Roe、John L. Turner

  DOI：10.1021/jm00352a014

  日期：1982.10

  reported N alpha- and N pi-benzylhistamines, were tested for agonist and antagonist activity at both H1 and H2 receptors. The results obtained indicate that introduction of a benzyl group into the histamine molecule causes a marked reduction in H1- or H2-agonist activity, and none of the compounds showed consistent antagonist activity. Evidently, the sterically demanding benzyl substituent is not easily

  作为旨在设计组胺H2受体拮抗剂的研究的一部分，描述了在组胺分子中各个位置引入苄基取代基对组胺能活性的影响。报道了新的4-苄基，β-苄基和4，N tau-二苯甲基组胺的新的合成方法以及所报道的2-苄基组胺。通过我们报道的用于合成N tau-甲基组胺的通用途径合成了新颖的N tau-苄基组胺。测试了这些苄基组胺以及已报道的Nα-和N pi-苄基组胺对H1和H2受体的激动剂和拮抗剂活性。获得的结果表明，向组胺分子中引入苄基会导致H1-或H2-激动剂活性显着降低，并且没有一种化合物显示出一致的拮抗剂活性。
• A convenient synthesis of 1,4-disubstituted imidazoles
  作者：Yong He、Yingzhong Chen、Hongwang Du、Lesley A Schmid、Carl J Lovely

  DOI：10.1016/j.tetlet.2004.05.011

  日期：2004.7

  An efficient method for the regioselective protection of 4-alkyl-, 4-iodo, 4-vinylimidazoles has been developed via an alkylation–isomerization sequence with various imidazole-protecting groups. The initially formed mixture of 4/5-alkyl-, 4/5-iodo, and 4/5-vinylimidazoles are isomerized to the corresponding 4-isomers on treatment of a DMF solution with a small amount of RX and heating at 75 °C.

  通过具有各种咪唑保护基的烷基化-异构化序列，已经开发出一种有效的区域选择性保护4-烷基-，4-碘，4-乙烯基咪唑的方法。在用少量RX处理DMF溶液并在75°C加热的情况下，将最初形成的4 / 5-烷基-，4 / 5-碘和4 / 5-乙烯基咪唑的混合物异构化为相应的4-异构体。
• US8921388B2
  申请人：——

  公开号：US8921388B2

  公开（公告）日：2014-12-30